<DOC>
	<DOCNO>NCT03018340</DOCNO>
	<brief_summary>To assess efficacy pimavanserin compare placebo give adjunctively selective serotonin reuptake inhibitor ( SSRI ) /serotonin-norepinephrine reuptake inhibitor ( SNRI ) antidepressant treatment patient Major Depressive Disorder ( MDD ) inadequate response antidepressant therapy</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Adjunctive Pimavanserin Major Depressive Disorder ( CLARITY )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>1 . Adult patient , age 18 year 2 . A clinical diagnosis major depressive disorder ( MDD ) 3 . Is treated one follow SSRI SNRI antidepressant monotherapy : Citalopram Escitalopram Paroxetine Fluoxetine Sertraline Duloxetine Venlafaxine Desvenlafaxine Venlafaxine XR 4 . Has history inadequate response antidepressant treatment 1 . Patient psychotic disorder MDD 2 . Patient current evidence serious and/or unstable neurologic , cardiovascular , respiratory , gastrointestinal , renal , hepatic , hematologic , medical disorder , include cancer malignancy , would affect patient 's ability participate program 3 . Patient history symptom long QT syndrome Patients evaluate screening ensure criterion study participation met . Patients may exclude study base assessment ( specifically determine baseline health psychiatric condition meet prespecified entry criterion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>